These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles. Zhang H, Huang Y, Fayad R, Spear GT, Qiao L. J Virol; 2004 Aug; 78(15):8342-8. PubMed ID: 15254206 [Abstract] [Full Text] [Related]
5. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target. Manocha M, Pal PC, Chitralekha KT, Thomas BE, Tripathi V, Gupta SD, Paranjape R, Kulkarni S, Rao DN. Vaccine; 2005 Dec 01; 23(48-49):5599-617. PubMed ID: 16099080 [Abstract] [Full Text] [Related]
7. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles. Kang CY, Luo L, Wainberg MA, Li Y. Biol Chem; 1999 Mar 01; 380(3):353-64. PubMed ID: 10223338 [Abstract] [Full Text] [Related]
8. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. Liu XS, Abdul-Jabbar I, Qi YM, Frazer IH, Zhou J. Virology; 1998 Dec 05; 252(1):39-45. PubMed ID: 9875315 [Abstract] [Full Text] [Related]
9. Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice. Akagi T, Kawamura M, Ueno M, Hiraishi K, Adachi M, Serizawa T, Akashi M, Baba M. J Med Virol; 2003 Feb 05; 69(2):163-72. PubMed ID: 12683403 [Abstract] [Full Text] [Related]
10. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Deml L, Schirmbeck R, Reimann J, Wolf H, Wagner R. Virology; 1997 Aug 18; 235(1):26-39. PubMed ID: 9300034 [Abstract] [Full Text] [Related]
12. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. McBurney SP, Young KR, Ross TM. Virology; 2007 Feb 20; 358(2):334-46. PubMed ID: 17011011 [Abstract] [Full Text] [Related]
15. AIDS vaccine: Intranasal immunization using inactivated HIV-1-capturing core-corona type polymeric nanospheres. Akagi T, Ueno M, Hiraishi K, Baba M, Akashi M. J Control Release; 2005 Dec 05; 109(1-3):49-61. PubMed ID: 16256237 [Abstract] [Full Text] [Related]
19. Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins. Visciano ML, Diomede L, Tagliamonte M, Tornesello ML, Asti V, Bomsel M, Buonaguro FM, Lopalco L, Buonaguro L. Vaccine; 2011 Jul 12; 29(31):4903-12. PubMed ID: 21596074 [Abstract] [Full Text] [Related]
20. Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses. Huang X, Liu L, Ren L, Qiu C, Wan Y, Xu J. Vaccine; 2007 Dec 17; 25(52):8874-84. PubMed ID: 18061316 [Abstract] [Full Text] [Related] Page: [Next] [New Search]